The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the beleaguered ...

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

As a numerical comparison, Keytruda monotherapy achieved a 45% ORR in first-line PD-L1 high patients ... drug conjugates and bispecific antibodies. "ESMO 2024: TIGIT race tightens with first ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Novartis, meanwhile, handed rights to TIGIT antibody ociperlimab to BeiGene a year ago, two years after paying $300 million upfront for an option on the drug. Like PD-1/PD-L1, TIGIT is thought to ...

At the European Society for Medical Oncology (ESMO) Congress 2024, GSK and iTeos finally provided the first data reveal of their TIGIT inhibitor, belrestotug, in combination with Jemperli (dostarlimab ...

locally advanced or metastatic PD-L1 high non-small cell lung cancer (NSCLC). Belrestotug is iTeos’ Fc active human immunoglobulin G1, or IgG1, monoclonal antibody targeting T cell immunoglobulin and ...